W. R. Berkley Corp (WRB)
Official siteFINANCIAL SERVICES • INSURANCE - PROPERTY & CASUALTY • NYSE
Market Cap: $28.77B
Last updated: Nov 17, 2026 at 11:06 AM ET
W. R. Berkley Corp (WRB) Stock Forecast
Analysts expect W. R. Berkley (WRB) to earn $4.95 per share in the fiscal year ending Dec 31, 2026, on revenue of $12.77B. Of 18 analysts, 2 rate the stock Buy or Strong Buy, 9 Hold and 7 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 13 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 18 ratings average 3.44, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 39% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 2 | 11.1% |
| Hold | 9 | 50.0% |
| Sell | 4 | 22.2% |
| Strong Sell | 3 | 16.7% |
- Consensus
- Hold
- Total analysts
- 18
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 2.0% and revenue estimates rise 3.1%.
- Fiscal year ending Dec 31, 2026
- $4.95
- EPS consensus, revenue $12.77B
- Fiscal year ending Dec 31, 2027
- $4.85
- EPS consensus, revenue $13.17B
- Next report
- Jan 25, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $4.95 | $4.86 to $5.05 | 17 | $12.77B | $12.70B to $12.93B | 7 |
| Dec 31, 2027 | $4.85 | $4.52 to $5.20 | 17 | $13.17B | $13.07B to $13.33B | 7 |
Quarterly Estimates
The EPS consensus rises from $1.21 for the quarter ending Dec 31, 2026 to $1.22 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.21 | $1.13 to $1.33 | 19 | $3.89B | $3.74B to $4.07B | 9 |
| Mar 31, 2027 | $1.22 | $1.14 to $1.27 | 14 | $3.24B | $3.20B to $3.28B | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 23 upward and 16 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 13 | 2 |
| Fiscal year ending Dec 31, 2027 | 5 | 6 |
| Quarter ending Mar 31, 2027 | 5 | 8 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.6% from $4.87.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $4.95 | $4.95 | $4.91 | $4.88 | $4.87 | +1.6% |
| Fiscal year ending Dec 31, 2027 | $4.85 | $4.85 | $4.87 | $4.84 | $4.83 | +0.6% |
| Quarter ending Mar 31, 2027 | $1.22 | $1.22 | $1.22 | $1.22 | $1.22 | -0.1% |
Frequently Asked Questions About WRB
What is the WRB stock forecast?
Consensus analyst estimates put W. R. Berkley's EPS at $4.95 for the fiscal year ending Dec 31, 2026, on revenue of $12.77B. The consensus rating from 18 analysts is Hold.
How do analysts rate WRB stock?
Of 18 analysts covering W. R. Berkley, 0 rate it Strong Buy, 2 Buy, 9 Hold, 4 Sell and 3 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from WRB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $4.95, with estimates from $4.86 to $5.05 from 17 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $4.85, with estimates from $4.52 to $5.20 from 17 analysts.
What revenue do analysts expect from W. R. Berkley next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $12.77B, with estimates from $12.70B to $12.93B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $13.17B, with estimates from $13.07B to $13.33B.
How many analysts cover WRB?
18 analysts rate W. R. Berkley stock, and 17 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
WRB pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors